NEW YORK (AP) — Martin Shkreli must return $64.6 million in profits he and his former company reaped from jacking up the price and monopolizing the market for a lifesaving drug, a federal judge ruled Friday while also barring the provocative, imprisoned ex-CEO from the pharmaceutical industry for the rest of his life.
Summary
- FILE - Former Turing Pharmaceuticals CEO Martin Shkreli attends the House Committee on Oversight and Reform Committee hearing on Capitol Hill in Washington, Feb. 4, 2016.
- A federal judge on Friday, Jan. 14, 2022 ordered Shkreli to return $64.6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from participating in the pharmaceutical industry for the rest of his life.
- A federal judge on Friday, Jan. 14, 2022 ordered Shkreli to return $64.6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from participating in the pharmaceutical industry for the rest of his life.
- Former Vyera CEO Kevin Mulleady agreed to pay $250,000 if he violates the settlement, which barred him from working for a pharmaceutical company” for seven years.
- The trial record included evidence showing Shkreli kept in regular contact with company executives, even after he went to prison.